This prospective, multicenter observational registry aims to establish a QFR-based quality control standard system for coronary revascularization in patients with coronary artery disease. The study will enroll over 10,000 patients with visually estimated at least one main branch coronary stenosis ≥50% from more than 50 centers across China (covering provincial, municipal, and county-level hospitals). Coronary angiographic images and intracoronary imaging (if available) will be collected and retrospectively analyzed by an independent core laboratory. The primary endpoint is QFR acquisition accessibility, defined as the mean of QFR usage proportion across centers.
Age ≥18 years
Coronary angiography showing visually estimated at least one main branch coronary stenosis ≥50% in patients with acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction >4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) who undergo PCI or receive conservative treatment
Ability to understand the study design and provide written informed consent
ST-segment elevation myocardial infarction within 4 weeks of onset
History of coronary artery bypass grafting (CABG) or planned CABG within 6 months
Inability to undergo coronary angiography
Non-cardiac cause with expected survival <1 year
Patients with coronary angiography showing visually estimated at least one main branch coronary stenosis ≥50% who present with asymptomatic ischemia, stable angina, unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction (\>4 weeks after onset) and undergo PCI or receive conservative treatment at one of the participating centers.
Cohort
Prospective
Not listed
QFR Adoption Rate
Defined as the mean across participating centers of the proportion of patients undergoing QFR assessment among eligible patients at each center.
MACE
A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization
Death
Cardiovascular, non-cardiovascular and undetermined death
MI
Target vessel related and non-target vessel related MI
Target vessel revascularization (TVR)
The ischemia driven and non-ischemia driven TVR
Click on the lead sponsor to view all of their trials.
China National Center for Cardiovascular Diseases
Lead sponsor
Guangdong Provincial People's Hospital
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Sir Run Run Shaw Hospital
Collaborator
Fuwai Huazhong Cardiovascular Hospital
Collaborator
Fuwai Yunnan Cardiovascular Hospital
Collaborator
Second Hospital of Jilin University
Collaborator
